Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is developing telaprevir in collaboration with Tibotec.

"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."

PROVE 1 Summary

-- 88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.<
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015  Victoria Vein & Surgery Clinic ... the Astanza Duality laser in Victoria, Texas ... as well as advanced laser treatments for a variety of ... tattoo industry to provide more services for their patients. Since ... many Victoria residents get rid of ...
(Date:3/27/2015)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is celebrating a key milestone ... Complete Knee System. ,   ... first introduced the NexGen knee system, with its innovative design ... implantations of the NexGen knee have taken place worldwide. ... demonstrates the importance of design innovation and component quality for surgeons and ...
(Date:3/27/2015)... , March 27, 2015 Report ... for leading ophthalmic drug companies  What does ... pharma ophthalmic industry ? Visiongain,s brand new report shows ... and prospects there. Our 242-page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Zimmer Celebrates Key Milestones For NexGen Complete Knee System 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
... PALO ALTO, Calif.--(BUSINESS WIRE)--Jun 25, 2007 - ... 2 clinical,trial results for Hematide(TM) were presented ... in Barcelona, Spain by Iain C.,Macdougall, M.D., ... Macdougall's poster included data in previously-treated,dialysis patients ...
... also Showed Sustained Improvements in Blood Glucose,Control ... 23, 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and ... a study that showed BYETTA(R) (exenatide) injection,sustained ... weight,loss through three and a half years ...
Cached Medicine Technology:Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 2Affymax Reports Phase 2 Clinical Dose Ranging Results of,Once-Per-Month Hematide for the Treatment of Anemia 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6
(Date:3/30/2015)... California (PRWEB) March 30, 2015 ... as radioactive isotopes, radiopharmaceuticals are used as tracers ... global market for radiopharmaceuticals is driven by the ... in the field of cardiology, neurology, pulmonology, and ... by the well-established use of radioisotopes in diagnostic ...
(Date:3/30/2015)... Daily sun exposure, stressors and environmental factors ... folds and other giveaways of age. However, advances in ... to hit the pause button, delaying the impact of ... or hack to rejuvenate any facial feature. , ... (AAFPRS) explores the intricacies of The Aging Face ...
(Date:3/30/2015)... March 30, 2015 Mid-America ATTC ... library of medications used in behavioral health and ... iPad and Android—is a convenient, electronic version of ... 1999. The useful resource provides up-to-date information on ... and frequency, side effects, emergency conditions, cautions, considerations ...
(Date:3/30/2015)... 2015 BioFit Engineered ... manufacturer of ergonomic seating solutions, now offers ... new upholsteries bolster the company’s existing selection ... providing disinfectable, green choices. , The BioFit ... purveyor CF Stinson. Six disinfectable patterns consisting ...
(Date:3/29/2015)... 2015 At the 2015 International Health ... introduced the new Fonda wall mounted heater and ... Club owners and facilities managers with saunas smaller than ... design of the Fonda heater. With an attractive ... an immediate upgrade for a sauna, especially when mounted ...
Breaking Medicine News(10 mins):Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 2Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 3Health News:Expanding Commercial Use in Nuclear Imaging Drives Demand for Radiopharmaceuticals, According to a New Report by Global Industry Analysts, Inc. 4Health News:New AAFPRS Infographic Addresses Concerns and Provides Aging Face Solutions 2Health News:Popular Publication on Behavioral Health Medications Now An App 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Helo Commercial Introduces Fonda Sauna Heater and Sauna and Steam Continuing Education Program at IHRSA 2
... new and novel computer modeling platform developed through intensive, ... and cities to be more prepared for catastrophic public ... American Medical Association,s Disaster Medicine and Public Health ... to Multihazard Modeling and Simulation," is based on the ...
... Telemedicine, Mammography and Health Screenings on Wheels Expand Access ... June 11 Kaiser Permanente, one of America,s leading ... a new generation of mobile health. A first-of-its-kind, 500-sq-foot, ... home island of Hawaii, known to many as the ...
... off brain cell damage, lab study finds , THURSDAY, June ... may start with one protein that somehow goes astray and ... say. , Mad cow disease is considered a prion disease ... prion protein, or PrP, which normally is found on the ...
... is pleased to offer its stock alerts service to ... move and in the news can receive FREE Alerts by visiting ... , Today,s focused alerts include: Hemispherx Biopharma, Inc. (Amex: ... Cell Therapeutics, Inc. (Nasdaq: CTIC ), Cancer Therapeutics Inc. ...
... June 11 National figures, stars from the world of sports ... gathered today in Anaheim, California to celebrate 20 years of Drug ... reach of every American in need at the National Association of ... , Speaking in front of a crowd representing every U.S. state ...
... most common cancers in China. Although the association between ... studied, the relation between smoking, alcohol drinking, family history ... cancer still remains uncertain. So it is important to ... of sporadic colorectal cancer. A research team led ...
Cached Medicine News:Health News:A new computer modeling program can help hospitals prepare for the worst 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 2Health News:Kaiser Permanente Unveils the Nation's Most Wired Mobile Health Vehicle 3Health News:Protein Branded As Culprit in Mad Cow Disease 2Health News:GlobalEquityReport.com Issues Cancer Stocks On The Move Today: HEB, GNBT, CTIC, CTHP, DNDN 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 2Health News:U.S. Drug Czar Addresses 2,500 Drug Court Professionals, Voices Strong Support for Expanding Drug Courts Throughout the Nation 3
... Autostat™II Rheumatoid Factor IgM enzyme linked immunosorbent ... (RF IgM). Enzyme-linked immunosorbent assay method for ... Factor in human serum. The results of ... as an aid in the diagnosis of ...
Rheumatoid Factor , R1: 4 X 20 ml buffer, R2: 2 X 8 ml antibody, Test / Kit: 320 (H717)...
... GALILEI Dual Scheimpflug Analyzer is a high ... three dimensional analysis of the anterior eye ... Scheimpflug Camera and a Placido Disk. , ... Placido imaging furnishes high accuracy curvature data, ...
EXTEND is an absorbable synthetic punctal implant that provides occlusion up to three months. It is packaged 20 implants per box in sizes of .0.3mm, 0.4mm, 0.5mm. A variety pack in also available w...
Medicine Products: